UBS Maintains Buy on Cardinal Health, Raises Price Target to $122
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health (NYSE:CAH) and increased the price target from $114 to $122.

January 29, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Kevin Caliendo reaffirmed a Buy rating on Cardinal Health and raised the price target to $122, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Kevin Caliendo from UBS typically suggests a strong conviction in the company's future performance and is often viewed positively by the market. This could lead to increased investor confidence and a potential short-term rise in the stock price of Cardinal Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100